These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22067520)

  • 41. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heart failure update.
    Gomes UC; Cleland JG
    Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S; Sundberg S; Lehtonen LA; Kleber FX
    J Am Coll Cardiol; 2004 Jun; 43(12):2177-82. PubMed ID: 15193677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients with advanced heart failure and the effects of levosimendan.
    Song ZZ; Ma J
    Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
    [No Abstract]   [Full Text] [Related]  

  • 45. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?
    Masarone D; Kittleson M; Pollesello P; Tedford RJ; Pacileo G
    Drugs; 2023 Feb; 83(3):195-201. PubMed ID: 36652192
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in positive inotropic therapy: levosimendan.
    Frishman WH
    Crit Care Med; 2003 Sep; 31(9):2408-9. PubMed ID: 14501979
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
    Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
    Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Use of levosimendan in cardiosurgical patients with chronic heart insufficiency].
    Eremenko AA; Kolpakov PE; Babaev MA; Revunenkov GV; Fominykh MV
    Anesteziol Reanimatol; 2010; (2):24-6. PubMed ID: 20524326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy.
    Séguéla PE; Mauriat P; Mouton JB; Tafer N; Assy J; Poncelet G; Nubret K; Iriart X; Thambo JB
    Arch Cardiovasc Dis; 2015; 108(6-7):347-55. PubMed ID: 25863426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of levosimendan in the treatment of heart failure.
    Kasikcioglu HA; Cam N
    Vasc Health Risk Manag; 2006; 2(4):389-400. PubMed ID: 17323593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension.
    Hansen MS; Andersen A; Holmboe S; Schultz JG; Ringgaard S; Simonsen U; Happé C; Bogaard HJ; Nielsen-Kudsk JE
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):232-238. PubMed ID: 28640039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug discovery and development for acute heart failure drugs: are expectations too high?
    Pollesello P
    Int J Cardiol; 2014 Mar; 172(1):11-3. PubMed ID: 24472177
    [No Abstract]   [Full Text] [Related]  

  • 55. Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin.
    Yilmaz MB; Karadas F; Erdem A; Tandogan I
    Int J Cardiol; 2008 Mar; 125(1):104-6. PubMed ID: 17428556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of Ca++-sensitizers for the treatment of heart failure.
    Lehmann A; Boldt J; Kirchner J
    Curr Opin Crit Care; 2003 Oct; 9(5):337-44. PubMed ID: 14508145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of levosimendan in children with cancer with severe acute cardiac dysfunction: case series and a review of the literature.
    Tosoni A; Dipchand AI; Mohseni-Bod H
    Cardiol Young; 2014 Jun; 24(3):524-7. PubMed ID: 23659288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical support and surgery of the failing heart: levosimendan.
    Toller W; Knez I
    Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pharmacological and mechanical support of the myocardium in perioperative period in cardio-surgical patients with chronic heart failure].
    Babaev MA; Eremenko AA; Ziuliaeva TP; Fedulova SV; Molochnikov IO; Fominykh MV; Poliakova PV; Dzemeshkevich SL
    Anesteziol Reanimatol; 2014; (3):34-9. PubMed ID: 25306682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The vasoactive-inotropic score and levosimendan: time for LVIS?
    Favia I; Vitale V; Ricci Z
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):e15-6. PubMed ID: 23507021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.